- AIPAC phase IIb data, including final overall survival data, reported in separate announcement
- Encouraging objective response rate (ORR) of 29.7% (11/37), including 5 out of 2 complete responsessd head and neck squamous cell carcinoma (HNSCC) patients in part C of the phase II trial TACTI-002
- TACTI-002 trial (part C) shows encouraging anti-tumor activity
- Total of 154 1st patients of the HNSCC line, not selected for PD-L1 expression, will be enrolled in the phase II study TACTI-003 to determine ORR as the primary endpoint
- Webcast for Global Investors to be held at 8:00 a.m. on November 17, 2021 (Sydney time) – details below
SYDNEY, AUSTRALIA, November 10, 2021 (GLOBE NEWSWIRE) – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, is pleased to to announce that data from its AIPAC, TACTI Studies -002 and TACTI-003 have been published in summaries available through the links below on the official website of the SITC 2021 Annual Meeting or on the website of the society.
Three poster presentations with additional data and commentary not included in the summaries will be available at https://www.sitcancer.org/2021/home starting November 12, 2021 at 7 a.m. EST and made available at Immutep’s website at www. immutep.com.
Title: Results of a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with non-selected second-line metastatic squamous cell carcinoma of the head and neck (HNSCC) PD-L1 .
Title: A phase II study of eftilagimod alpha (LAG-3 protein) and pembrolizumab in patients not screened for PD-L1 expression in metastatic squamous cell carcinoma of the head and neck (HNSCC).
To note: A separate announcement detailing AIPAC’s results was also released today.
Title: AIPAC Final Results: A phase IIb comparing eftilagimod alpha (a LAG-3 protein) soluble to placebo in combination with weekly paclitaxel in HR + HER2-MBC.
Immutep will present AIPAC data in a global investor webcast. The details are as follows:
Date and time: 8:00 a.m. AEDT (Sydney) Wednesday, November 17, 2021
4:00 p.m. EST (New York) Tuesday, November 16, 2021
10 p.m. CET (Berlin) Tuesday November 16, 2021
Questions: Investors are encouraged to submit their questions in advance via [email protected]
Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutics related to LAG-3 for the treatment of cancer and autoimmune diseases. Immutep is committed to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value.
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-class antigen-presenting cell (APC) activator currently being explored in the world. cancer and infectious diseases. Immutep is also developing an LAG-3 agonist (IMP761) for autoimmune diseases.
Other LAG-3 products, including antibodies for modulating the immune response, are under development by Immutep’s major pharmaceutical partners.
Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.
Further information can be found on the company’s website www.immutep.com or by contacting:
Australian Investors / Media:
Catherine Strong, Citadelle-MAGNUS
+61 (0) 406 759 268; [email protected]
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]